4 results about "Ventricular function" patented technology

The application discloses a method, system, device, medium and product for evaluating right ventricular function, and relates to the technical field of medical image processing and ultrasonic diagnosis. The method comprises the following steps: acquiring a sequence of multiple two-dimensional ultrasonic images of a right ventricle of a heart and spatial pose information of the sequence, and generating point cloud data; identifying an end-diastolic frame, an end-systolic frame and an anatomical structure point, and acquiring sparse point cloud data of the anatomical structure point; constructing a three-dimensional grid model of the end-diastolic frame and the end-systolic frame; determining multiple tracking points of a tricuspid annulus and acquiring a three-dimensional coordinate trajectory; calculating longitudinal displacement, area change rate and peak time dispersion based on the trajectory, and completing function evaluation. The application overcomes the limitations of angle dependence and point substitution of traditional TAPSE technology, realizes comprehensive evaluation of right ventricular function from three dimensions of longitudinal displacement, area change rate and systolic synchrony, and improves the accuracy and clinical value of evaluation.

The application provides use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in preparation of a drug for treating or preventing pulmonary arterial hypertension, which can effectively improve right ventricular hypertrophy, right ventricular function damage and hemodynamic parameters of an animal model of the pulmonary arterial hypertension, delay or improve excessive proliferation of arterial endothelial cells and smooth muscle cells in the pulmonary arterial hypertension, treat vascular remodeling and vascular muscularization of a pulmonary arterial hypertension patient, and has a good protective effect on a heart in the pulmonary arterial hypertension.

Disclosed herein, in some aspects, are systems and methods for treating hypertrophic cardiomyopathy (HCM) in a subject. In some embodiments, the systems and methods described herein comprise monitoring a cardiac performance and optionally detecting an abnormality of said cardiac performance, in some cases after an initial HCM treatment is administered. In some cases, the initial HCM treatment includes administration of a myosin inhibitor, and / or septal myectomy. In some embodiments, said cardiac performance correlates with a right ventricular function and / or a pulmonary arterial pressure. In some embodiments, systems and methods described herein comprise identifying a therapy for a subject so as to help reduce the risk of de-performance teriorating a cardiac performance. In some cases, identifying the therapy includes predicting an effectiveness of a therapy with respect to a cardiac performance. In some embodiments, a recommendation is provided for adjusting a therapy based on an observed effect on a cardiac performance.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin and its application; the traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin is composed of ginseng and salvia miltiorrhiza; this invention finds that the traditional Chinese medicine composition can promote the survival rate of doxorubicin-induced cardiomyocyte H9c2, reduce doxorubicin-induced apoptosis of cardiomyocyte H9c2, reduce doxorubicin-induced oxidative stress damage and cardiac damage, improve left ventricular function, and improve doxorubicin-induced cardiotoxicity, which is of great significance for the prevention and treatment of azithromycin-induced cardiotoxicity.